Log in to search using one of your social media accounts:

 

Treatment deintensification in human papillomavirus ‐positive oropharynx cancer: Outcomes from the National Cancer Data Base
CONCLUSIONSDeintensification of treatment from chemoradiotherapy to radiotherapy or surgery alone in cases of HPV+ AJCC eighth edition stage I or stage II disease may compromise patient safety. Treatment intensification to triple‐modality therapy for patients with stage III disease may improve survival in this group. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 15, 2017 Category: Cancer & Oncology Authors: Shayan Cheraghlou, Phoebe K. Yu, Michael D. Otremba, Henry S. Park, Aarti Bhatia, Cheryl K. Zogg, Saral Mehra, Wendell G. Yarbrough, Benjamin L. Judson Tags: Original Article Source Type: research

Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population ‐based study among older breast cancer patients
CONCLUSIONSAdjuvant chemotherapy is associated with a small but significant increase in the risk of AML and MDS, especially with regimens that include A. Longer follow‐up is needed to confirm that risk is not increased with the recently adopted TC regimen. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 14, 2017 Category: Cancer & Oncology Authors: Aron S. Rosenstock, Jiangong Niu, Sharon H. Giordano, Hui Zhao, Antonio C. Wolff, Mariana Chavez ‐MacGregor Tags: Original Article Source Type: research

The role of postmastectomy radiotherapy in patients with stage II breast cancer
(Source: Cancer)
Source: Cancer - December 12, 2017 Category: Cancer & Oncology Authors: Nisha Ohri, Bruce G. Haffty, Thomas A. Buchholz Tags: Cancer Case Conundrums Source Type: research

Erratum: Chang Y ‐J, Wang Y, Mo X‐D, et al. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long‐term outcomes of a prospective randomized trial. Cancer. 2017;123: 2881‐2892.
(Source: Cancer)
Source: Cancer - December 12, 2017 Category: Cancer & Oncology Tags: Erratum Source Type: research

Prostate cancer screening with prostate ‐specific antigen: Where are we going?
Current prostate‐specific antigen screening is not cost‐effective from a public health perspective. A new algorithm using genetic testing and imaging has yet to be developed. See also pages 000‐000. (Source: Cancer)
Source: Cancer - December 12, 2017 Category: Cancer & Oncology Authors: Peter C. Albertsen Tags: Editorial Source Type: research

Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance
CONCLUSIONSProstate‐specific antigen–based prostate cancer screening in the United States between the ages of 55 and 69 years, as recommended by the USPSTF, may be cost‐effective at a $100,000 threshold but only with a quadrennial screening frequency and with AS offered to all low‐risk men. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 12, 2017 Category: Cancer & Oncology Authors: Tiago M. de Carvalho, Eveline A. M. Heijnsdijk, Harry J. de Koning Tags: Original Article Source Type: research

Body composition in long ‐term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity
CONCLUSIONSSarcopenic obesity is prevalent in long‐term survivors of ALL, and this places them in double jeopardy from excess body fat and inadequate SMM (eg, a combination of metabolic and frailty syndromes). It is associated with an adverse impact on overall HRQL. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 12, 2017 Category: Cancer & Oncology Authors: Christopher J. C. Marriott, Lesley F. Beaumont, Troy H. Farncombe, Amy N. Cranston, Uma H. Athale, Valerie N. Yakemchuk, Colin E. Webber, Ronald D. Barr Tags: Original Article Source Type: research

Travel distance and stereotactic body radiotherapy for localized prostate cancer
BACKGROUNDDefinitive stereotactic body radiotherapy (SBRT) represents an emerging and debated treatment option for patients with prostate cancer, with potential economic savings and reports of short‐term efficacy since 2006. The current study sought to define national trends in definitive prostate SBRT use and determine whether patterns vary by travel distance for treatment. METHODSThe National Cancer Data Base identified 181,544 men with localized prostate cancer who were treated with definitive external beam radiotherapy from 2004 through 2012. Joinpoint regression analyzed definitive prostate SBRT trends over time, wh...
Source: Cancer - December 12, 2017 Category: Cancer & Oncology Authors: Brandon A. Mahal, Yu ‐Wei Chen, Roshan V. Sethi, Oscar A. Padilla, David D. Yang, Janice Chavez, Vinayak Muralidhar, Jim C. Hu, Felix Y. Feng, Karen E. Hoffman, Neil E. Martin, Daniel E. Spratt, James B. Yu, Peter F. Orio, Paul L. Nguyen Tags: Original Article Source Type: research

Patient ‐reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes
CONCLUSIONSThe FA‐IPSS(h) is a novel patient‐centered prognostic index that includes patients' self‐reported fatigue severity. The authors believe its use might enhance physicians' ability to predict survival more accurately in patients with advanced MDS. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 12, 2017 Category: Cancer & Oncology Authors: Fabio Efficace, Francesco Cottone, Gregory Abel, Pasquale Niscola, Gianluca Gaidano, Franck Bonnetain, Amelie Anota, Giovanni Caocci, Angel Cronin, Luana Fianchi, Massimo Breccia, Reinhard Stauder, Uwe Platzbecker, Giuseppe A. Palumbo, Mario Luppi, Rosang Tags: Original Article Source Type: research

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
CONCLUSIONSGuadecitabine has promising clinical activity and an acceptable safety profile and thus warrants further development in this population. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Gail J. Roboz, Hagop M. Kantarjian, Karen W. L. Yee, Patricia L. Kropf, Casey L. O'Connell, Elizabeth A. Griffiths, Wendy Stock, Naval G. Daver, Elias Jabbour, Ellen K. Ritchie, Katherine J. Walsh, David Rizzieri, Scott D. Lunin, Tania Curio, Woonbok Chun Tags: Original Article Source Type: research

Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG ‐ACRIN Cancer Research Group (E4203)
CONCLUSIONSTS expression was prognostic: Patients with TS‐L tumors who received FOLFOX/Bev had a longer PFS than those with TS‐H tumors, along with a trend toward longer OS. Patients with TS‐H tumors did not benefit more from IROX/Bev than from FOLFOX/Bev. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Neal J. Meropol, Yang Feng, Jean L. Grem, Mary F. Mulcahy, Paul J. Catalano, John S. Kauh, Michael J. Hall, Joel N. Saltzman, Thomas J. George, Jeffrey Zangmeister, Elena G. Chiorean, Puneet S. Cheema, Peter J. O'Dwyer, Al B. Benson Tags: Original Article Source Type: research

Adoption of evidence ‐based novel therapies in the treatment of gastric cancer: A national observational study
CONCLUSIONSPractice patterns for the treatment of gastric cancer in the United States reflect the increased adoption of evidence‐based therapies, including endoscopic resection of early‐stage cancer and preoperative therapy for patients with locally advanced disease. Treatment for metastatic disease remains markedly underused. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Ali A. Mokdad, Amna Ali, Adam C. Yopp, Patricio M. Polanco, Ibrahim Nassour, John C. Mansour, Michael A. Choti, Rebecca M. Minter, Sam C. Wang, Matthew R. Porembka Tags: Original Article Source Type: research

The efficacy of prostate ‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials
CONCLUSIONSThe observed cancer mortality reduction in screening trials appears to be highly sensitive to trial protocol and practice settings. Accounting for these differences, the efficacy of PSA screening in the PLCO setting is not necessarily inconsistent with ERSPC results. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Harry J. de Koning, Roman Gulati, Sue M. Moss, Jonas Hugosson, Paul F. Pinsky, Christine D. Berg, Anssi Auvinen, Gerald L. Andriole, Monique J. Roobol, E. David Crawford, Vera Nelen, Maciej Kwiatkowski, Marco Zappa, Marcos Luj án, Arnauld Villers, Tiago Tags: Original Article Source Type: research

Trends in botanical dietary supplement use among US adults by cancer status: The National Health and Nutrition Examination Survey, 1999 to 2014
BACKGROUNDPatients with cancer may use botanical dietary supplements (BDS) in an attempt to manage the side effects of chemotherapy, yet evidence about BDS use among patients with cancer is limited. The authors examined trends in BDS use among US adults according to cancer status and patient characteristics. METHODSA serial, cross‐sectional study was conducted using data from the National Health and Nutrition Examination Survey from 1999 through 2014 (n = 43,644). Self‐reported cancer diagnosis history and any BDS use in the preceding 30 days were determined. The prevalence of BDS use was calculated in ea...
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Chao Li, Richard A. Hansen, Chiahung Chou, Angela I. Calder ón, Jingjing Qian Tags: Original Article Source Type: research

Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013
BACKGROUNDThere is a paucity of information about treatment and mortality trends after acute myocardial infarction (AMI) for cancer survivors (CS). METHODSIn this population‐based study, the authors compared temporal trends of treatments and outcomes (mortality, nonfatal cardiovascular outcomes), among CS and patients without cancer (the noncancer patient [NCP] group) with AMI in Ontario (Canada) using inverse probability treatment weight (IPTW)‐adjusted modeling. RESULTSOf 270,089 patients with AMI (22,907 CS, 247,182 NCP, 1995‐2013; median follow‐up, 10.1 and 11.0 years, respectively), the use of invasive coronar...
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Inna Y. Gong, Andrew T. Yan, Dennis T. Ko, Craig C. Earle, Winson Y. Cheung, Stuart Peacock, Marlous Hall, Chris P. Gale, Kelvin K. W. Chan Tags: Original Article Source Type: research

Risk of recurrence, prognosis, and follow ‐up for Danish women with cervical cancer in 2005‐2013: A national cohort study
CONCLUSIONSThis study has identified a group of women at FIGO stage 1A1 in no need of specialized, hospital‐based follow‐up. Many of the recurrences at FIGO stage 1B1 are asymptomatic, and this may show a need for follow‐up in this group. Further prospective investigation is needed. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Gry Assam Taarnh øj, Ib Jarle Christensen, Henrik Lajer, Katrine Fuglsang, Mette Moustgaard Jeppesen, Henriette Strøm Kahr, Claus Høgdall Tags: Original Article Source Type: research

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next ‐generation sequencing: A clinical and molecular analysis of 423 patients
CONCLUSIONSOverall, TERT promoter alterations were among the most prevalent aberrations in this population, with very high rates in brain cancers (48% of patients) and melanomas (56% of patients). These aberrations frequently coexist with a high number of other aberrations, with the latter feature also significantly associated with poorer overall survival. Therapeutic options for targeting tumors with TERT promoter mutations are currently limited, although a variety of novel approaches are under development. Cancer 2017. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Socie...
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Maria Schwaederle, Nithya Krishnamurthy, Gregory A. Daniels, David E. Piccioni, Santosh Kesari, Paul T. Fanta, Richard B. Schwab, Sandip P. Patel, Barbara A. Parker, Razelle Kurzrock Tags: Original Article Source Type: research

Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers
The objective of this study was to describe characteristics at diagnosis and outcomes of adults with soft tissue sarcoma. METHODSThe authors conducted a retrospective multicenter study of 12,262 patients who were treated between January 1980 and 31 December 2013 in French Sarcoma Group centers and enrolled in the “Conticabase.” Diagnoses were systematically reviewed by expert pathologists, and entities were classified according to the 2013 World Health Organization classification. Diagnostic characteristics, treatments, and outcomes are described for the entire cohort, for the subgroup of patients with transloc...
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Nicolas Penel, Jean ‐Michel Coindre, Antoine Giraud, Philippe Terrier, Dominique Ranchere‐Vince, Françoise Collin, Sophie L. E. Guellec, Céline Bazille, Marick Lae, Gonzague de Pinieux, Isabelle L. Ray‐Coquard, Sylvie Bonvalot, Axel L. E. Cesne, Y Tags: Original Article Source Type: research

Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial
BACKGROUNDStrategies to improve bone health care in men receiving androgen deprivation therapy (ADT) are not consistently implemented. The authors conducted a phase 2 randomized controlled trial of 2 education‐based models‐of‐care interventions to determine their feasibility and ability to improve bone health care. METHODSA single‐center parallel‐group randomized controlled trial of men with prostate cancer who were receiving ADT was performed. Participants were randomized 1:1:1 to 1) a patient bone health pamphlet and brief recommendations for their family physician (BHP+FP); 2) a BHP and support from a bone hea...
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Shabbir M.H. Alibhai, Henriette Breunis, Narhari Timilshina, Maryam S. Hamidi, Angela M. Cheung, George A. Tomlinson, Tharsika Manokumar, Osai Samadi, Joanna Sandoval, Sara Durbano, Padraig Warde, Jennifer M. Jones Tags: Original Article Source Type: research

“Epigenetic” modification as therapy for acute myeloid leukemia
The benefits and limitations of the treatment of acute myeloid leukemia/myelodysplasia with epigenetic modifiers are discussed. See also pages 000‐000. (Source: Cancer)
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Charles A. Schiffer Tags: Editorial Source Type: research

Immune checkpoint inhibitors in advanced non –small cell lung cancer
The emergence of immune checkpoint inhibitors for the treatment of cancer has led to major changes to the therapeutic landscape of lung cancer. Improvements in overall survival relative to standard chemotherapy have been observed in the first‐line and second‐line therapy settings for patients with advanced non–small cell lung cancer (NSCLC) who are treated with immune checkpoint inhibitors. Consequently, every patient with advanced‐stage NSCLC is now a candidate for immune checkpoint inhibitor therapy. However, it is clear that the benefit from therapy is not universal, and identification of biomarkers to selec...
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Hazem I. Assi, Alice O. Kamphorst, Nour M. Moukalled, Suresh S. Ramalingam Tags: Review Article Source Type: research

Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study
CONCLUSIONSNo evidence was found for the idea that early radiologic response to chemotherapy is prognostic for survival for patients with RMS. Treatment adaptation based on early response (except for patients with PD) should, therefore, no longer be incorporated into future studies. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Bas Vaarwerk, Johanna H. van der Lee, Willemijn B. Breunis, Daniel Orbach, Julia C. Chisholm, Nathalie Cozic, Meriel Jenney, Rick R. van Rijn, Kieran McHugh, Soledad Gallego, Heidi Glosli, Christine Devalck, Mark N. Gaze, Anna Kelsey, Christophe Bergeron, Tags: Original Article Source Type: research

Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases
BACKGROUNDExtrapulmonary neuroendocrine carcinomas (NECs) are poorly studied and are managed similar to lung NECs, which may not account for differences between the 2 groups of tumors as well as the heterogeneity within extrapulmonary NEC. METHODSData from the Surveillance, Epidemiology, and End Results program between 1973 and 2012 were used to estimate the relative percentages of lung NECs and subgroups of extrapulmonary NECs, epidemiological patterns at these sites, and the median and 5‐year overall survival rates. RESULTSOf 162,983 NEC cases, 14,732 were extrapulmonary; of these, 5509 were gastrointestinal (37.44%), ...
Source: Cancer - December 6, 2017 Category: Cancer & Oncology Authors: Arvind Dasari, Kathan Mehta, Lauren A. Byers, Halfdan Sorbye, James C. Yao Tags: Original Article Source Type: research

Erratum: Epperla N, Maddocks KJ, Salhab M, et al. C ‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy. Cancer. 2017;123:4411‐4418.
(Source: Cancer)
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Tags: Erratum Source Type: research

2017 Thank you to peer reviewers
(Source: Cancer)
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Tags: Information Item Source Type: research

Women who undergo HPV testing receive earlier detection and treatment of cervical precancers
(Source: Cancer)
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Carrie Printz Tags: CancerScope Source Type: research

Secondhand smoke exposure declines among nonsmoking cancer survivors
(Source: Cancer)
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Carrie Printz Tags: CancerScope Source Type: research

First person: Julie Vose, MD, MBA
(Source: Cancer)
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Carrie Printz Tags: CancerScope Source Type: research

Issue Information – TOC
(Source: Cancer)
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Tags: Issue Information Source Type: research

Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study
BACKGROUNDSedentary behaviors are associated with poor health outcomes in the general population, but their clinical impact on adult survivors of childhood acute lymphoblastic leukemia (ALL) has not been characterized to date. In the current study, we described the prevalence of sedentary behaviors in survivors of ALL and examined associations between time spent sedentary and body composition and onset of cardiovascular disease (CVD) risk factors. METHODSParticipants' self‐reported screen time (eg, television, computer) and activity as measured by accelerometer were used to determine activity time (sedentary, light activ...
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Carrie R. Howell, Carmen L. Wilson, Matthew J. Ehrhardt, Robyn E. Partin, Sue C. Kaste, Jennifer Q. Lanctot, Ching ‐Hon Pui, Leslie L. Robison, Melissa M. Hudson, Kirsten K. Ness Tags: Original Article Source Type: research

Impact of latency time on survival for adolescents and young adults with a second primary malignancy
CONCLUSIONSMost AYAs who develop an SPM do so within 1 to 5 years of their primary cancer diagnosis, and they have an increased risk of death from cancer in comparison with AYAs with an SPM developing after longer survivorship intervals. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Melanie Goldfarb, Aaron S. Rosenberg, Qian Li, Theresa H. M. Keegan Tags: Original Article Source Type: research

Conditional survival of patients with gastric cancer who undergo curative resection: A multi ‐institutional analysis in China
CONCLUSIONSThe current results indicate that CDS estimates for Chinese patients with gastric cancer who underwent surgery were dynamic and increased with time elapsed. Patients who had unfavorable tumor characteristics had the greatest improvement in CDS. This valuable information could provide more a precise evaluation of long‐term prognosis and may serve as an important prognostic index in clinical practice. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Pengliang Wang, Zhe Sun, Wei Wang, Jingyu Deng, Zhenning Wang, Han Liang, Zhiwei Zhou, Huimian Xu Tags: Original Article Source Type: research

Anamorelin (ONO ‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)
This study examined the efficacy and safety of anamorelin (ONO‐7643), a novel selective ghrelin receptor agonist, in Japanese cancer patients with cachexia. METHODSThis double‐blind clinical trial (ONO‐7643‐04) enrolled 174 patients with unresectable stage III/IV non–small cell lung cancer (NSCLC) and cachexia in Japan. Patients were randomized to daily oral anamorelin (100 mg) or a placebo for 12 weeks. The primary endpoint was the change from the baseline LBM (measured with dual‐energy x‐ray absorptiometry) over 12 weeks. The secondary endpoints were changes in appetite, body weight, quality of l...
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama, Tateaki Naito, Masashi Kondo, Kouzo Yamada, Hiromoto Kitajima, Kozo Yoshimori, Kazuhiro Sato, Hiroshi Saito, Keisuke Aoe, Tetsuya Tsuji, Yuichi Takiguchi, Koichi Takayama, Naoyuki Komura, Toru Takiguchi, K Tags: Original Article Source Type: research

Cancer cachexia: Are we ready to take a step forward?
The field of cancer cachexia at both the preclinical and clinical levels will benefit from the further investigation and refinement of its mechanisms and further study of potential agents to define the best treatment outcomes for patients. In the meantime, the availability of anamorelin, a promising agent in the clinic would be extremely valuable to move that research forward. See also pages 000‐000. (Source: Cancer)
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Jeffrey Crawford Tags: Editorial Source Type: research

Is less more? Comparing chemotherapy alone with chemotherapy and radiation for high ‐risk grade 2 glioma: An analysis of the National Cancer Data Base
This study compares the OS of patients with high‐risk grade 2 gliomas treated with CA versus CRT. METHODSPatients with high‐risk grade 2 gliomas (subtotal resection or age ≥ 40 years) with oligodendrogliomas, astrocytomas, or mixed tumors were identified with the National Cancer Data Base. Patients were grouped into CA and CRT cohorts. Univariate analyses and multivariate analyses (MVAs) were performed. Propensity score (PS) matching was also implemented. The Kaplan‐Meier method was used to analyze OS. RESULTSA total of 1054 patients with high‐risk grade 2 gliomas were identified: 496 (47.1%) recei...
Source: Cancer - December 4, 2017 Category: Cancer & Oncology Authors: Jaymin Jhaveri, Yuan Liu, Mudit Chowdhary, Zachary S. Buchwald, Theresa W. Gillespie, Jeffrey J. Olson, Alfredo D. Voloschin, Bree R. Eaton, Hui ‐Kuo G. Shu, Ian R. Crocker, Walter J. Curran, Kirtesh R. Patel Tags: Original Article Source Type: research

Opioid use among cancer survivors: A call to action for oncology and primary care providers
(Source: Cancer)
Source: Cancer - November 30, 2017 Category: Cancer & Oncology Authors: Larissa Nekhlyudov, Olaf P. Geerse, Catherine M. Alfano Tags: Correspondence Source Type: research

Reply to Opioid use among cancer survivors: A call to action for oncology and primary care providers
(Source: Cancer)
Source: Cancer - November 30, 2017 Category: Cancer & Oncology Authors: Rinku Sutradhar, Lisa Barbera Tags: Correspondence Source Type: research

A mutational comparison of adult and adolescent and young adult (AYA) colon cancer
CONCLUSIONSThe current results provide the rationale for a more comprehensive study with a larger sample set and experimental validation of the functional impact of the identified variants along with their contribution to the biologic and clinical characteristics of AYA colon cancer. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - November 30, 2017 Category: Cancer & Oncology Authors: James V. Tricoli, Lisa A. Boardman, Rajesh Patidar, Sivasish Sindiri, Jin S. Jang, William D. Walsh, Paul M. McGregor, Corinne E. Camalier, Michele G. Mehaffey, Wayne L. Furman, Armita Bahrami, P. Mickey Williams, Chih ‐Jian Lih, Barbara A. Conley, Jave Tags: Original Article Source Type: research

Lung cancer incidence and the strength of municipal smoke ‐free ordinances
CONCLUSIONSComprehensive smoke‐free laws were associated with fewer new cases of lung cancer, whereas weak or moderate smoke‐free laws did not confer the same benefit. One hundred percent smoke‐free laws, covering all workers and the public with few or no exceptions, may be key in reducing new cases of lung cancer. [See related editorial on pages 000‐000, this issue.] Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - November 28, 2017 Category: Cancer & Oncology Authors: Ellen J. Hahn, Mary Kay Rayens, Amanda T. Wiggins, Wenqi Gan, Holly M. Brown, Timothy W. Mullett Tags: Original Article Source Type: research

The life ‐saving power of policy: Lessons from Kentucky
Data from Kentucky clearly link comprehensive smoke‐free ordinances to lower rates of lung cancer. Uniform smoke‐free policies protect nonsmokers from secondhand smoke, encourage cessation in those who are still smoking, and save lives. See also pages 000‐000. (Source: Cancer)
Source: Cancer - November 28, 2017 Category: Cancer & Oncology Authors: Matthew A. Steliga Tags: Editorial Source Type: research

Literacy analysis of National Comprehensive Cancer Network patient guidelines for the most common malignancies in the United States
CONCLUSIONSOverall, the assessment indicates high demand scores for the readability and complexity of the NCCN patient guidelines and thus that the materials are not quite suitable for the general US adult population. Further input from patient focus groups to address appropriateness and usefulness is critical. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - November 27, 2017 Category: Cancer & Oncology Authors: Bao Ngoc N. Tran, Qing Z. Ruan, Sherise Epstein, Joseph A. Ricci, Rima E. Rudd, Bernard T. Lee Tags: Original Article Source Type: research

Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell ‐free DNA by next‐generation sequencing
CONCLUSIONSBecause only a small fraction of total cfDNA might be derived from tumor cells, only mutations with the first allele frequency pattern may be regarded as tumor‐specific mutations in cfDNA. Effective filtering of background mutations will be required to improve the accuracy of mutation calls in cfDNA. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - November 27, 2017 Category: Cancer & Oncology Authors: Jacqueline F. Wang, Xingxiang Pu, Xiaoshan Zhang, Ken Chen, Yuanxin Xi, Jing Wang, Xizeng Mao, Jianhua Zhang, John V. Heymach, Mara B. Antonoff, Wayne L. Hofstetter, Reza J. Mehran, David C. Rice, Jack A. Roth, Boris Sepesi, Stephen G. Swisher, Ara A. Vap Tags: Original Article Source Type: research

The Reply to the letter on the cost ‐effectiveness of human papillomavirus in Punjab further distorts the scientific record
(Source: Cancer)
Source: Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Vivian Suman, Jacob M. Puliyel Tags: Correspondence Source Type: research

Leptomeningeal metastasis from systemic cancer: Review and update on management
Leptomeningeal metastasis is an uncommon and typically late complication of cancer with a poor prognosis and limited treatment options. Diagnosis is often challenging, with nonspecific presenting symptoms ranging from headache and confusion to focal neurologic deficits, such as cranial nerve palsies. Standard diagnostic evaluation involves a neurologic examination, magnetic resonance imaging of the brain and spine with gadolinium, and cytologic evaluation of the cerebral spinal fluid. Therapy entails a multimodal approach focused on palliation with surgery, radiation, and/or chemotherapy, which may be administered systemic...
Source: Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Nancy Wang, Mia S. Bertalan, Priscilla K. Brastianos Tags: Review Article Source Type: research

Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epstein ‐Barr virus in situ assays
(Source: Cancer)
Source: Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Vivian Wai Yan Lui, Ka ‐Fai To, Kwok‐Wai Lo Tags: Correspondence Source Type: research

Reply to Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epstein ‐Barr virus in situ assays
(Source: Cancer)
Source: Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Siraj M. Ali, Jeffrey S. Ross, Kai Wang Tags: Reply to Correspondence Source Type: research

Physician interpretation of genomic test results and treatment selection
CONCLUSIONSPhysicians are aware of recurrent mutations in actionable genes on “hotspot” panels. As larger genomic panels are used, there may be a growing need for annotation of actionability. Decision support to increase awareness of genomically relevant trials and novel treatment options for recurrent mutations (eg, KRAS) also are needed. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Lauren L. Brusco, Chetna Wathoo, Kenna R. Mills Shaw, Vijaykumar R. Holla, Ann M. Bailey, Amber M. Johnson, Yekaterina B. Khotskaya, Beate C. Litzenburger, Nora S. Sanchez, Jia Zeng, Elmer V. Bernstam, Cathy Eng, Bryan K. Kee, Rodabe N. Amaria, Mark J. Ro Tags: Original Article Source Type: research

Factors affecting compliance with confirmatory colonoscopy after a positive fecal immunochemical test in a national colorectal screening program
CONCLUSIONSThe government could improve the screening rate by training case managers to assist in following patients until they complete colonoscopy, subsidizing sedated colonoscopies, and providing health education not only to the general public but also to physicians. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - November 22, 2017 Category: Cancer & Oncology Authors: Shao ‐Yi Cheng, Ming‐Chieh Li, Shu‐Li Chia, Kuo‐Chin Huang, Tai‐Yuan Chiu, Ding‐Cheng Chan, Han‐Mo Chiu Tags: Original Article Source Type: research

Social integration and survival after diagnosis of colorectal cancer
CONCLUSIONSSocially integrated women were found to have better survival after a diagnosis of CRC, possibly due to beneficial caregiving from their family and friends. Interventions aimed at strengthening social network structures to ensure access to care may be valuable programmatic tools in the management of patients with CRC. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - November 21, 2017 Category: Cancer & Oncology Authors: Elizabeth A. Sarma, Ichiro Kawachi, Elizabeth M. Poole, Shelley S. Tworoger, Edward L. Giovannucci, Charles S. Fuchs, Ying Bao Tags: Original Article Source Type: research

Course and predictors of post ‐traumatic stress disorder in a cohort of psychologically distressed patients with cancer: A 4‐year follow‐up study
CONCLUSIONSThe overall rates of PTSD decreased with time, but one‐third of patients (34.1%) who were initially diagnosed had persistent or worsening PTSD 4 years later. There is a need for early identification of this subset of patients who have cancer with PTSD to design risk‐targeted interventions. Cancer 2017. © 2017 American Cancer Society. (Source: Cancer)
Source: Cancer - November 20, 2017 Category: Cancer & Oncology Authors: Caryn Mei Hsien Chan, Chong Guan Ng, Nur Aishah Taib, Lei Hum Wee, Edward Krupat, Fremonta Meyer Tags: Original Article Source Type: research